Press "Enter" to skip to content

Top Bristol-Myers shareholder comes out against $74 billion Celgene deal

Bristol-Myers Squibb Co’s top shareholder Wellington Management said on Wednesday that it does not support the U.S. drugmaker’s $74 billion purchase of biotech Celgene Corp, imperiling what would be the largest pharmaceutical company takeover of all time.

Also Read:   U.S. coronavirus deaths top 100,000 as country reopens